Silence Therapeutics (SLN) Equity Average: 2019-2025
Historic Equity Average for Silence Therapeutics (SLN) over the last 1 years, with Sep 2025 value amounting to $84.1 million.
- Silence Therapeutics' Equity Average was N/A to $84.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $84.1 million, marking a year-over-year change of. This contributed to the annual value of $78.0 million for FY2024, which is 217.02% up from last year.
- Per Silence Therapeutics' latest filing, its Equity Average stood at $84.1 million for Q3 2025, which was down 18.70% from $103.4 million recorded in Q2 2025.
- In the past 5 years, Silence Therapeutics' Equity Average registered a high of $130.4 million during Q4 2024, and its lowest value of $8.4 million during Q1 2022.
- Its 3-year average for Equity Average is $92.3 million, with a median of $96.4 million in 2024.
- Data for Silence Therapeutics' Equity Average shows a peak YoY soared of 288.14% (in 2024) over the last 5 years.
- Over the past 5 years, Silence Therapeutics' Equity Average (Quarterly) stood at $17.0 million in 2021, then reached $8.4 million in 2022, then spiked by 173.37% to $23.0 million in 2023, then spiked by 288.14% to $130.4 million in 2024, then spiked by 38.05% to $84.1 million in 2025.
- Its Equity Average was $84.1 million in Q3 2025, compared to $103.4 million in Q2 2025 and $123.4 million in Q1 2025.